Literature DB >> 26759823

Optimization of solid lipid nanoparticles prepared by a single emulsification-solvent evaporation method.

Deep Pooja1, Lakshmi Tunki1, Hitesh Kulhari2, Bharathi B Reddy1, Ramakrishna Sistla1.   

Abstract

This data article contains the data related to the research article "Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of rifampicin" (Pooja et al. 2015) [1]. In the present study, SLN were prepared by a single emulsification-solvent evaporation method and the various steps of SLN preparation are shown in a flow chart. The preparation of SLN was optimized for various formulation variables including type and quantity of lipid, surfactant, amount of co-surfactant and volume of organic phase. Similarly, effect of variables related to homogezation, sonication and stirring processes, on the size and surface potential of SLN was determined and optimized.

Entities:  

Keywords:  Formulation parameters; Optimization; Process variables; Single emulsification-solvent evaporation; Solid lipid nanoparticles

Year:  2015        PMID: 26759823      PMCID: PMC4683325          DOI: 10.1016/j.dib.2015.11.038

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of data The article describes the preparation, optimization and characterization of solid lipid nanoparticles. The data can be useful for other researchers investigating the effects of different lipids and surfactants on size and surface charge of nanoparticles. The optimized formulation parameters could be used for the development of solid lipid nanoparticles of hydrophobic drugs.

Experimental design, material and methods

Solid lipid nanoparticles (SLN) i.e. lipid nanoparticles with solid matrix is the most fascinating carrier for oral drug delivery because of their excellent biocompatibility, high drug loading, long-term stability and feasibility for large scale production [1], [2], [3], [4], [5]. In this study, solid lipid nanoparticles (SLN) were prepared by a single emulsification-solvent evaporation method. Fig. 1 presents the various steps of preparation of SLN. Various formulation parameters (Table 1) and process variables (Table 2) were optimized on the basis of their effect on particle size, polydispersity index and zeta potential. These parameters included type and quantity of lipid and surfactant, quantity of co-surfactant, volume of organic phase, homogenization speed and time, sonication time, stirring speed and time. Formulations were prepared by changing one parameter at a time while keeping other parameters constant.
Fig. 1

Flow chart representing the preparation of solid lipid nanoparticles.

Table 1

Optimization of various formulation parameters for the preparation of solid lipid nanoparticles.

FormulationVariablePD (nm)PDIZP (mV)
Type of lipid
F1GMS10055.53±2.40.23±0.04−23.2±2.1
F2Tristearin100157.5±6.70.35±0.11−26.9±2.3
F3Tripalmitin100119.5±3.90.43±0.08−22.1±1.9
Quantity of lipid (mg)
F4GMS8049.28±3.10.27±0.09−21.8±1.6
F1GMS10055.53±2.40.23±0.04−23.2±2.1
F6GMS12055.09±3.70.30±0.02−29.7±2.3
Type and concentration of surfactant (%w/v)
F7Tween 80166.67±2.50.36±0.12−31.8±2.4
F1Tween 801.555.53±2.40.23±0.04−23.2±2.1
F8Tween 802133.2±5.60.27±0.08−26.6±1.8
F9Poloxomer 188161.4±4.40.38±0.09−29.9±2.3
F10Poloxomer 1881.565.7±3.90.40±0.12−26.4±2.1
F11Poloxomer 188264.9±2.80.39±0.10−23.5±2.5
F12PVA1120.92±6.10.15±0.09−32.0±1.9
F13PVA1.5108.84±4.30.20±0.07−26.6±2.4
F14PVA2102.86±4.80.21±0.11−24.5±1.8
Volume of organic solvent (mL)
F15CHCl3148.91±2.40.36±0.11−19.6±1.4
F16CHCl3252.81±1.90.21±0.07−24.3±2.6
F1CHCl3355.53±2.40.23±0.04−23.2±2.1
F17CHCl3547.73±2.60.25±0.04−23.7±2.3
Quantity of co-surfactant (mg)
F16lecithin soy2052.81±1.90.21±0.07−24.3±2.6
F18lecithin soy3047.54±2.30.21±0.09−25.5±1.8
F19lecithin soy4050.32±3.10.28±0.10−28.6±2.4

GMS: Glyceryl monostearte; PVA: Polyvinyl alcohol; PD: Particle diameter, PDI: Polydispersity index; ZP: Zeta potential.

Table 2

Optimization of various process variables for preparation solid lipid nanoparticles.

FormulationVariablePD (nm)PDIZP (mV)
Homogenization speed (rpm)
F20500064.67±4.80.56±0.03−27.5±2.5
F18800047.54±2.30.21±0.09−25.5±1.8
211100044.43±3.10.26±0.03−26.5±2.1
Homogenization time (min)
F223157.92±5.70.45±0.05−30.3±3.1
F23476.21±3.90.28±0.07−25.8±2.8
F21544.43±3.10.26±0.03−26.5±2.1
F24671.23±4.80.29±0.11−23.9±2.7
Sonication time (min)
F255>500
F2610135.45±6.70.32±0.13−27.1±2.9
F211544.43±3.10.26±0.03−26.5±2.1
F272049.89±2.80.24±0.09−25.8±2.6
Stirring speed (rpm)
F2880059.02±3.90.25±0.05−20.1±1.9
F21100044.43±3.10.26±0.03−26.5±2.1
F29120067.82±4.20.27±0.02−22.9±2.5
Stirring time (h)
F30169.48±4.50.42±0.07−28.4±2.7
F31257.37±5.10.31±0.05−26.4±1.8
F21344.43±3.10.26±0.03−26.5±2.1
F32461.34±3.80.25±0.09−26.2±2.5

Optimization of formulation variables

Type and quantity of lipids

Three different lipids viz. glyceryl monostearte (GMS), tristearin and tripalmitin were used as lipid matrix. The particle diameter (PD), polydispersity index (PDI) and zeta potential (ZP) were measured using a Zetasizer NanoZS (Malvern, UK). The lipid showing minimum PD and PDI was selected and used in three different quantities (80, 100 and 120 mg).

Type and concentration of surfactants

The type and concentration of surfactant affect the particle size as well as stability of nanoparticles. At low concentration, surfactant will not be sufficient to cover the surface of nanoparticles resulting into increased particle size due to particle aggregation. High concentration of surfactant may lead to bridging between nanoparticles and may also cause toxicity. Therefore, three different surfactants (Tween®80, Poloxomer 188 and polyvinyl alcohol) were evaluated at three different concentrations (1%, 1.5% and 2% w/v).

Volume of organic phase

The organic solvent is used to dissolve the lipids and chloroform was used in this study in varying volumes (1–5 mL). The formulation showing good particle size with minimum volume of solvent was selected.

Quantity of co-surfactant

Lecithin soy was used as co-surfactant which act as internal emulsifier and favors to particle size reduction and stability. Lecithin soy was used at different concentration (20, 30 and 40) to get a formulation having small particle size, less PDI with good zeta potential and stability.

Optimization of process variables

Homogenization speed and time, sonication time and stirring speed and time

The organic phase was poured in aqueous surfactant phase and homogenized at different speed (5000, 8000 and 11000 rpm) for different time (3, 4, 5 and 6 min) to get course emulsion. Then this course emulsion was sonicated for different time period to get a nanoemulsion. Finally formulation was stirred to evaporate the organic solvent and to get the nanoparticles. The formulation was stirred at different speed (800, 1000, and 1200 rpm) and for different time period (1, 2 and 3 h) for optimization.
Subject areaChemistry, lipids and biology
More specific subject areaTargeted nanomedicine
Type of dataTable and figure
How data was acquiredParticle size, polydispersity index and surface charge (Zetasizer, NanoZS, Malvern)
Data formatRaw and analyzed
Experimental factorsFormulation and process parameters were changed for optimization of size and zeta potential of nanoparticles.
Experimental featuresVarious formulations were prepared by single emulsification- solvent evaporation method to get nanoparticles of desired size and zeta potential.
Data source locationNA
Data accessibilityThe data are presented in this article
  4 in total

1.  Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of Rifampicin.

Authors:  Deep Pooja; Lakshmi Tunki; Hitesh Kulhari; Bharathi B Reddy; Ramakrishna Sistla
Journal:  Chem Phys Lipids       Date:  2015-09-26       Impact factor: 3.329

2.  Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles.

Authors:  Mi-Kyung Lee; Soo-Jeong Lim; Chong-Kook Kim
Journal:  Biomaterials       Date:  2007-01-10       Impact factor: 12.479

3.  Production of solid lipid nanoparticles (SLN): scaling up feasibilities.

Authors:  A Dingler; S Gohla
Journal:  J Microencapsul       Date:  2002 Jan-Feb       Impact factor: 3.142

4.  Physical-Chemical Characterization and Formulation Considerations for Solid Lipid Nanoparticles.

Authors:  Harsh Chauhan; Sarat Mohapatra; Daniel J Munt; Shantanu Chandratre; Alekha Dash
Journal:  AAPS PharmSciTech       Date:  2015-08-21       Impact factor: 3.246

  4 in total
  15 in total

1.  Purification of Drug Loaded PLGA Nanoparticles Prepared by Emulsification Solvent Evaporation Using Stirred Cell Ultrafiltration Technique.

Authors:  Suresh K Paswan; T R Saini
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

Review 2.  Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.

Authors:  Hira Choudhury; Manisha Pandey; Pei Xin Chin; Yee Lin Phang; Jeng Yuen Cheah; Shu Chien Ooi; Kit-Kay Mak; Mallikarjuna Rao Pichika; Prashant Kesharwani; Zahid Hussain; Bapi Gorain
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 3.  Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases.

Authors:  Christos Tapeinos; Matteo Battaglini; Gianni Ciofani
Journal:  J Control Release       Date:  2017-08-26       Impact factor: 9.776

4.  Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization.

Authors:  Nikita Lomis; Susan Westfall; Leila Farahdel; Meenakshi Malhotra; Dominique Shum-Tim; Satya Prakash
Journal:  Nanomaterials (Basel)       Date:  2016-06-15       Impact factor: 5.076

Review 5.  A Promising Biocompatible Platform: Lipid-Based and Bio-Inspired Smart Drug Delivery Systems for Cancer Therapy.

Authors:  Min Woo Kim; Seung-Hae Kwon; Jung Hoon Choi; Aeju Lee
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

6.  Influence of Solvent Evaporation Technique Parameters on Diameter of Submicron Lamivudine-Poly-ε-Caprolactone Conjugate Particles.

Authors:  Tomasz Urbaniak; Witold Musiał
Journal:  Nanomaterials (Basel)       Date:  2019-08-31       Impact factor: 5.076

7.  Fabrication and Assessment of Diosgenin Encapsulated Stearic Acid Solid Lipid Nanoparticles for Its Anticancer and Antidepressant Effects Using in vitro and in vivo Models.

Authors:  Hina Khan; Sadia Nazir; Rai Khalid Farooq; Ishaq N Khan; Aneela Javed
Journal:  Front Neurosci       Date:  2022-02-10       Impact factor: 4.677

Review 8.  Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems.

Authors:  Vijay Mishra; Kuldeep K Bansal; Asit Verma; Nishika Yadav; Sourav Thakur; Kalvatala Sudhakar; Jessica M Rosenholm
Journal:  Pharmaceutics       Date:  2018-10-18       Impact factor: 6.321

9.  Phytol-Loaded Solid Lipid Nanoparticles as a Novel Anticandidal Nanobiotechnological Approach.

Authors:  Tábata L C Lima; Luanda B F C Souza; Lannya C S Tavares-Pessoa; Alaine M Dos Santos-Silva; Rômulo S Cavalcante; Raimundo F de Araújo-Júnior; Alianda M Cornélio; Matheus F Fernandes-Pedrosa; Guilherme Maranhão Chaves; Arnóbio Antônio da Silva-Júnior
Journal:  Pharmaceutics       Date:  2020-09-13       Impact factor: 6.321

10.  Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer.

Authors:  Taylor Smith; Kevin Affram; Ebony L Nottingham; Bo Han; Felix Amissah; Sunil Krishnan; Jose Trevino; Edward Agyare
Journal:  Sci Rep       Date:  2020-10-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.